VIDEO: RBX2660 restores microbiome, bile acid composition in C. difficile infection
Click Here to Manage Email Alerts
SAN DIEGO — RBX2660, an investigational live biotherapeutic, restored microbiome and bile acid composition concurrent with clinical response in patients with Clostridioides difficile, according to research at Digestive Disease Week 2022.
“This poster is three different takes on how RBX2660 is aimed at restoring the microbiome and the data that we saw in three clinical trials,” Ken Blount, PhD, chief scientific officer at Rebiotix, a Ferring company, and vice president of microbiome research at Ferring Pharmaceuticals, said in a Healio video exclusive. “This is the largest analysis of its kind — we've combined three different clinical trials including two large, randomized, double-blinded, placebo-controlled trials. We're very proud to report that this is a poster of distinction.”
Collapse
Blount K, et al. Poster Su1596. Presented at: Digestive Disease Week; May 21-24, 2022; San Diego (hybrid meeting).
Read more about
Click Here to Manage Email Alerts